PRIME designation for Bavarian Nordic's RSV vaccine

Bavarian Nordic (OMX: BAVA) has announced that its respiratory syncytial virus (RSV) vaccine candidate for the prevention of RSV in older adults has been granted PRIME eligibility by the European Medicines Agency (EMA).

There are no approved vaccines for RSV, and the granting of PRIME designation suggests that the clinical data overall show the potential of the vaccine, named MVA-BN-RSV, to address the unmet medical need in the proposed target population.

RSV is a common virus that usually causes mild, cold-like symptoms, but in serious cases can lead to severe lung infections, including bronchiolitis and pneumonia, which ultimately can lead to death. Currently, there is no approved vaccine against the virus.